MORRISTOWN, N.J.--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced that it has completed its target enrollment for DISCOVER 2 (“Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response”), the second global, Phase 3 clinical trial of Durata’s lead product candidate, dalbavancin, under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria.
